NASDAQ: ARDX | Healthcare / Biotechnology / USA |
3.95 | +0.2900 | +7.92% | Vol 8.22M | 1Y Perf 207.56% |
Sep 22nd, 2023 16:00 DELAYED |
BID | 3.95 | ASK | 4.00 | ||
Open | 3.84 | Previous Close | 3.66 | ||
Pre-Market | - | After-Market | 3.95 | ||
- - | - -% |
Target Price | 5.75 | Analyst Rating | Strong Buy 1.00 | |
Potential % | 45.57 | Finscreener Ranking | ★★★ 48.51 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★ 38.37 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★ 45.63 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 70.88 | Earnings Rating | Strong Buy | |
Market Cap | 860.56M | Earnings Date | 2nd Nov 2023 | |
Alpha | 0.02 | Standard Deviation | 0.24 | |
Beta | 1.16 |
Today's Price Range 3.624.00 | 52W Range 1.095.13 | 5 Year PE Ratio Range -2.90-5.20 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Sell |
Performance | |||
---|---|---|---|
1 Week | -13.19% | ||
1 Month | 7.63% | ||
3 Months | 9.72% | ||
6 Months | -2.71% | ||
1 Year | 207.56% | ||
3 Years | -28.83% | ||
5 Years | -4.82% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -48.97 | |||
ROE last 12 Months | -168.04 | |||
ROA (5Y Avg) | -40.64 | |||
ROA last 12 Months | -78.88 | |||
ROC (5Y Avg) | -40.37 | |||
ROC last 12 Months | -88.91 | |||
Return on invested Capital Q | -21.72 | |||
Return on invested Capital Y | -25.63 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 2.80 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-3.40 | ||||
8.05 | ||||
63.90 | ||||
58.30 | ||||
-6.40 | ||||
-0.89 | ||||
8.05 | ||||
0.36 | ||||
484.60M | ||||
Forward PE | -26.76 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.80 | ||||
2.30 | ||||
0.09 | ||||
0.56 | ||||
-26.00 | ||||
Leverage Ratio | 2.20 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
89.40 | ||||
-1 219.80 | ||||
-1 218.00 | ||||
-2 042.30 | ||||
- |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
7.98M | ||||
0.04 | ||||
121.17 | ||||
- |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2023 | -0.12 | -0.08 | 33.33 |
Q01 2023 | -0.11 | -0.13 | -18.18 |
Q04 2022 | 0.01 | 0.06 | 500.00 |
Q03 2022 | -0.17 | -0.14 | 17.65 |
Q02 2022 | -0.19 | -0.19 | 0.00 |
Q01 2022 | -0.20 | -0.21 | -5.00 |
Q04 2021 | -0.25 | -0.31 | -24.00 |
Q03 2021 | -0.34 | -0.42 | -23.53 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
9/2023 QR | -0.11 | 8.33 | Positive |
12/2023 QR | -0.05 | 0.00 | - |
12/2023 FY | -0.38 | 11.63 | Positive |
12/2024 FY | -0.17 | -1 600.00 | Negative |
Next Report Date | 2nd Nov 2023 |
Estimated EPS Next Report | -0.11 |
Estimates Count | 5 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 8.22M |
Shares Outstanding | 217.86K |
Shares Float | 205.88M |
Trades Count | 27.99K |
Dollar Volume | 31.60M |
Avg. Volume | 6.40M |
Avg. Weekly Volume | 7.81M |
Avg. Monthly Volume | 6.44M |
Avg. Quarterly Volume | 4.96M |
Ardelyx Inc. (NASDAQ: ARDX) stock closed at 3.95 per share at the end of the most recent trading day (a 7.92% change compared to the prior day closing price) with a volume of 8.22M shares and market capitalization of 860.55M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 88 people. Ardelyx Inc. CEO is Michael G. Raab.
The one-year performance of Ardelyx Inc. stock is 207.56%, while year-to-date (YTD) performance is 38.6%. ARDX stock has a five-year performance of -4.82%. Its 52-week range is between 1.09 and 5.125, which gives ARDX stock a 52-week price range ratio of 70.88%
Ardelyx Inc. currently has a PE ratio of -3.40, a price-to-book (PB) ratio of 8.05, a price-to-sale (PS) ratio of 63.90, a price to cashflow ratio of 58.30, a PEG ratio of -, a ROA of -78.88%, a ROC of -88.91% and a ROE of -168.04%. The company’s profit margin is -%, its EBITDA margin is -1 218.00%, and its revenue ttm is $7.98 Million , which makes it $0.04 revenue per share.
Of the last four earnings reports from Ardelyx Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.11 for the next earnings report. Ardelyx Inc.’s next earnings report date is 02nd Nov 2023.
The consensus rating of Wall Street analysts for Ardelyx Inc. is Strong Buy (1), with a target price of $5.75, which is +45.57% compared to the current price. The earnings rating for Ardelyx Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Ardelyx Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Ardelyx Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 9.84, ATR14 : 0.29, CCI20 : -114.85, Chaikin Money Flow : 0.00, MACD : 0.01, Money Flow Index : 35.06, ROC : -16.49, RSI : 45.23, STOCH (14,3) : 24.44, STOCH RSI : 0.33, UO : 32.49, Williams %R : -75.56), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Ardelyx Inc. in the last 12-months were: Blanks Robert (Option Excercise at a value of $113 999), Blanks Robert (Option Exercise at a value of $113 999), Blanks Robert (Sold 75 741 shares of value $272 674 ), David M. Mott (Buy at a value of $1 000 641), David P. Rosenbaum (Sold 1 948 shares of value $3 797 ), Elizabeth Grammer (Sold 1 242 shares of value $2 421 ), Grammer Elizabeth (Sold 5 298 shares of value $17 444 ), Justin A. Renz (Sold 7 816 shares of value $23 735 ), Laura Williams (Sold 1 241 shares of value $2 419 ), Michael G. Raab (Sold 6 219 shares of value $12 120 ), Raab Michael (Sold 36 225 shares of value $122 338 ), Robert Blanks (Sold 101 464 shares of value $152 853 ), Robert Ora Felsch (Sold 5 308 shares of value $17 180 ), Rodriguez Susan (Sold 15 030 shares of value $50 755 ), Rosenbaum David (Sold 17 957 shares of value $67 782 ), Susan Rodriguez (Sold 3 456 shares of value $6 736 ), Williams Laura (Sold 27 591 shares of value $92 948 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
CEO: Michael G. Raab
Telephone: +1 510 745-1700
Address: 34175 Ardenwood Boulrvard, Fremont 94555, CA, US
Number of employees: 88
Fri, 22 Sep 2023 12:51 GMT Analysts Conflicted on These Healthcare Names: Ardelyx (ARDX), Community Healthcare (CHCT) and Trulieve Cannabis (OtherTCNNF)
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.